Skip to main content
. Author manuscript; available in PMC: 2017 Aug 10.
Published in final edited form as: Am J Transplant. 2016 May 2;16(9):2563–2573. doi: 10.1111/ajt.13808

Figure 1. CTLA4-Ig treatment prevents acute heart allograft rejection but induces chronic allograft rejection (transplant vasculopathy).

Figure 1

(A) Survival curves of heart grafts transplanted into syngeneic and allogeneic C57BL/6 hosts with or without CTLA4-Ig treatment. The MST of Balb/c heart allografts in CTLA4-Ig-treated mice was ≈31 days, and the MST of the control group was 8 days. The syngeneic heart grafts survived indefinitely. (B) Hematoxylin and eosin staining of syngeneic and CTLA4-Ig-treated grafts at 30 days after transplantation showing tissue and vascular structure in the grafts as well as cellular infiltration. (C) Masson’s trichrome staining of heart transplants at 30 days after transplantation showing tissue and vascular fibrosis. Representative pictures of one of three grafts examined in each group are shown (*p < 0.05). CTLA4-Ig, CTLA4 immunoglobulin; MST, mean survival time.